Mikart, a pharmaceutical contract development and manufacturing organization (CDMO), has acquired a state-of-the-art Korsch XM12 to meet their pharmaceutical client demands for complex formulation development and production of oral solid dose products.
 
Mikart has a 45-year history as a CDMO for solid oral and liquid oral formulation development and manufacturing. 
 
“Adding this equipment will help our earlier clinical phase clients with the development of their fixed dose combination (FDC) products and potent compounds that require state-of-the-art compression technology for bilayer and mini tablets,” said Michael Kallelis, CEO, Mikart. “Korsch was able to provide the technology and platform for us to answer that call as we continue to expand our business.”
 
According to Kallelis, this is the first in a series of planned capital expenditures to leverage Mikart’s understanding in modified release, formulation development, and its core competencies in development, clinical and commercial scale manufacturing. 
 
Nazar Elkarim, vice president of pharmaceutical development services, said, “In addition to formulation and clinical trial production, Mikart offers the ability for our clients to work with potent compounds, under cGMP conditions, in our FDA approved facilities. Additional capabilities will also be added this year that increase formulation technologies at our Atlanta, Georgia facilities.”
 
Gus LaBella, director of formulation development, said, “The compression technology in the XM12, with its automated weight checking, advanced design, interchangeable turrets, and modern operating system will enable Mikart to take on complex bi-layer tablet projects and offer the flexibility requested by our clients.”